Pinnacle Associates Ltd. Has $38.53 Million Position in AbbVie Inc. $ABBV

Posted by Tammy Falkenburg on May 14th, 2026

Pinnacle Associates Ltd. cut its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 1.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 168,630 shares of the company’s stock after selling 2,789 shares during the quarter. Pinnacle Associates Ltd.’s holdings in AbbVie were worth $38,530,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Simmons Bank lifted its holdings in AbbVie by 1.1% during the 4th quarter. Simmons Bank now owns 50,824 shares of the company’s stock worth $11,613,000 after buying an additional 532 shares during the period. Bank Julius Baer & Co. Ltd Zurich increased its position in AbbVie by 13.0% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 90,857 shares of the company’s stock valued at $20,787,000 after purchasing an additional 10,447 shares during the period. Western Wealth Management LLC increased its position in AbbVie by 9.1% during the 4th quarter. Western Wealth Management LLC now owns 23,814 shares of the company’s stock valued at $5,441,000 after purchasing an additional 1,985 shares during the period. Allworth Financial LP increased its position in AbbVie by 8.4% during the 4th quarter. Allworth Financial LP now owns 264,206 shares of the company’s stock valued at $60,368,000 after purchasing an additional 20,372 shares during the period. Finally, Freemont Management S.A. increased its position in AbbVie by 1,030.0% during the 4th quarter. Freemont Management S.A. now owns 11,300 shares of the company’s stock valued at $2,582,000 after purchasing an additional 10,300 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Up 0.3%

AbbVie stock opened at $208.39 on Thursday. AbbVie Inc. has a 12-month low of $176.57 and a 12-month high of $244.81. The firm’s fifty day moving average is $211.23 and its 200 day moving average is $220.29. The company has a market capitalization of $368.17 billion, a PE ratio of 102.65, a PEG ratio of 0.72 and a beta of 0.32.

AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the previous year, the company earned $2.46 EPS. AbbVie’s quarterly revenue was up 12.4% compared to the same quarter last year. Sell-side analysts expect that AbbVie Inc. will post 14.32 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is currently 340.89%.

Insider Activity

In other news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.06% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: New immunology data and an upgraded 2026 earnings outlook are reinforcing confidence in AbbVie’s growth trajectory and valuation. A Look At AbbVie (ABBV) Valuation After New Immunology Data And Upgraded 2026 Earnings Outlook
Positive Sentiment: Analyst commentary continues to lean constructive, with recent coverage highlighting AbbVie as an attractive long-term healthcare name and pointing to a higher price target from Evercore ISI. Why AbbVie Inc. (ABBV) is One of the Best Healthcare Stocks to Buy for the Long Term
Positive Sentiment: Multiple recent articles argue AbbVie’s growth engine is “firing,” with bullish takes centered on its expanding drug portfolio and rising dividend, both supportive of investor sentiment. 3 Reasons to Buy AbbVie Stock (ABBV) Like There’s No Tomorrow
Neutral Sentiment: AbbVie appointed Kelly Sanderson Schrems as UK VP and General Manager, a routine leadership move that is unlikely to materially move the stock on its own. AbbVie Appoints Kelly Sanderson Schrems as UK VP and General Manager
Neutral Sentiment: Shareholders backed directors and maintained the governance structure at the annual meeting, which removes uncertainty but is not a major new catalyst. AbbVie Shareholders Back Directors, Maintain Governance Structure
Neutral Sentiment: Zacks and other commentary remain supportive, but this is mostly reinforcing existing optimism rather than introducing a major new catalyst. The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio

Wall Street Analyst Weigh In

A number of research firms have weighed in on ABBV. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. William Blair restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price on the stock in a report on Thursday, April 30th. Berenberg Bank set a $275.00 target price on shares of AbbVie in a report on Tuesday, January 20th. Finally, Guggenheim reaffirmed a “buy” rating and set a $249.00 target price on shares of AbbVie in a research note on Friday, May 1st. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $252.90.

Get Our Latest Stock Report on ABBV

AbbVie Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.